- Braxia Scientific will be participating at the PSYCH Investor Summit on July 7
Braxia Scientific Corp. (CSE: BRAX), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021.Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will be followed by a Q&A. Dr. McIntyre will also take part in a panel discussion, along with Canadian Securities Exchange CEO Richard Carleton, on “The Next 5-10 Years of Research & Development.”
About Braxia Scientific Corp.
Braxia Scientific, is a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders. The medical solutions company aims to reduce the illness burden of brain-based mental disorders such as major depressive disorder among others. Braxia Scientific is primarily focused on (i) owning and operating multidisciplinary clinics providing treatment for mental health disorders and (ii) research activities related to discovering and commercializing novel drugs and delivery methods. The Company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform. Braxia Scientific, through its wholly owned subsidiary, the Canadian Rapid Treatment Center of Excellence Inc., currently operates multidisciplinary community-based clinics offering rapid-onset treatments for depression located in Mississauga, Toronto, Ottawa, and Montreal.